Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Indoles
  • Meningeal Neoplasms
  • Meningioma
  • Pyrroles

abstract

  • Sunitinib is active in recurrent atypical/malignant meningioma patients. A randomized trial should be performed.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4483051

Digital Object Identifier (DOI)

  • 10.1093/neuonc/nou148

PubMed ID

  • 25100872

Additional Document Info

start page

  • 116

end page

  • 21

volume

  • 17

number

  • 1